Gene Therapy Update for Friedreich’s Ataxia What patients and families should know (March 2026) Who is Lexeo Therapeutics? Lexeo Therapeutics is a biotechnology company developing gene therapies for heart disease, including heart involvement caused by Friedreich’s ataxia (FA)—a major cause of illness and premature death in FA. What treatment is...
Researchers at The Neuro (Montreal Neurological Institute-Hospital) are currently evaluating a non-invasive electrical brain stimulation technique to temporarily relieve symptoms of Friedreich’s ataxia (FA). This international clinical study, conducted in Canada exclusively at The Neuro is exploring the use of transcranial direct current stimulation (tDCS) to reactivate brain circuits affected...
For Adolescent Patients and Parents/Caregivers of Pediatric Patients The BRAVE Study is evaluating a potential treatment option for Friedreich Ataxia. If your child has been diagnosed with Friedreich Ataxia (FA), they may be eligible for the BRAVE Study. About the BRAVE Study. The BRAVE Study is evaluating how safe a...
Message to the Friedreich Ataxia Community October 7, 2025 Dear Advocacy Partners and FA community members, This morning, we were pleased to share positive interim clinical data for LX2006, our investigational gene therapy, that includes both cardiac and neurological outcome measures. LX2006 (AAVrh10hFXN) is currently being studied in the Lexeo-sponsored...
Patient Information This brochure provides etails about the AROATXN2-1001 Study for individuals with spinocerebellar ataxia type 2 (SCA2)d. It aims to help potential participants decide whether they or someone they know may want to join the study. Eligibility Criteria You may be eligible to participate if you: Are between 18...
Conversation with women and men engaged in our foundation. Today, we present Sébastien HUYNH | LinkedIn. AC: Can you introduce your professional background? SH: My career has allowed me to develop broad skills in management, finance, and accounting. Having grown up in France, I have had the opportunity to work...
Posted on: 2023-10-18– Posted by: Ataxia Canada – Category: publications Deadline: November 18 2023 Dear Members, At the next annual general assembly on December 3rd 2023, we will renew and/or elect members to the Board of Directors. We are seeking to solicit nominations of bilingual candidates that satisfy some of...